Tim Hirst, PhD

Chief Executive Officer

Tim is the Chairman & CEO of GPN Vaccines. He has extensive expertise in the life sciences, executive management and venture capital investment. Tim was previously CEO of ANU Connect Ventures, a $30M pre-seed VC fund, the Deputy Vice Chancellor for Research & Innovation at The University of Sydney and Professor & Head of Microbiology at the University of Bristol, UK. He is an active angel investor working with investment groups throughout Australia and US to assist early stage companies to raise capital and develop their innovative technologies. Tim is also Chairman of Gamma Vaccines Pty Ltd, Brain Changer Pty Ltd, Flex-G Pty Ltd, Acting Chairman of Emudent Technologies Pty Ltd, Trustee Director of Griffin Accelerator Holdings Pty Ltd and an Honorary Adjunct Professor at the University of Adelaide.

Lauren Giorgio, PHD GAICD

Chief Operating Officer

Lauren is the Chief Operating Officer of GPN Vaccines. She brings valuable experience in intellectual property management, business development, stakeholder engagement, commercialisation and operations in the life sciences sector, having worked broadly across the pharmaceutical, medical device, digital health and diagnostic industries.  Lauren has spent her career working alongside world-leading academics and clinicians to commercialise medical research. Most recently, she led the Business Development Office at the Centre for Eye Research Australia and prior to this, was part of the Business Development team at the internationally acclaimed Walter and Eliza Hall Institute. Lauren has also been involved in the establishment, management and strategic direction of several small companies including OccuRx, Enlighten Imaging and Catalyst Therapeutics.

James Paton, PHD FAA

Chief Scientific Officer

James is a Professor of Microbiology and the Director of the Research Centre for Infectious Diseases at the University of Adelaide. He is Australia’s preeminent authority on the pathogenesis of S. pneumoniae and recently was South Australian Scientist of the Year (2017). James is a former NHMRC Australia Fellow and Senior Principle Research Fellow and he directs an internationally acclaimed team of researchers at the University of Adelaide. He has published over 370 research papers and in the last 8 years has raised over $36M in grants to support his research activities. James was the lead Chief Investigator on the ARC Linkage grant that led to the development of the Gamma-PN vaccine and the NHMRC Development Grant that is supporting its final preclinical development.

Paul Wabnitz, MD PhD MBA

Medical Director

Paul has extensive clinical, drug development and business experience from both Australia and the United States. Until recently, Paul was Medical Director at CMAX where he provided leadership, training and management to over 70 clinical staff and has been an investigator on over 35 Phase 1 and 2 trials across a wide range of therapeutic areas. He has been Principal Investigator and Medical Monitor on a number of trials testing biologicals, antibodies, vaccines and other novel therapies. Paul also held various senior leadership roles at Pfizer Global in Michigan spanning clinical pharmacology, drug metabolism, pharmacokinetics, toxicology and clinical trial development. Paul is currently a Training Specialist in Medical Oncology and Clinical Pharmacology at the Royal Adelaide Hospital and Flinders Cancer Clinic. He is also a primary reviewer on the Human Research Ethics Committees for the Central Adelaide Local Health Network and also Bellberry.

Jim Ackland

Director, Regulatory & Quality

Jim has over 45 years’ experience in the manufacture, quality control, development and international regulatory requirements for vaccine products. He has been involved in more than 20 vaccine development projects as the lead regulatory advisor and preclinical safety expert, and has filed dozens of successful clinical trial applications in the US, Europe and Australia. Jim spent 26 years at CSL Limited in Melbourne where he held various leadership positions in vaccine manufacture, quality assurance and research and development, including Head of Regulatory Affairs for Vaccine Products. Following this, he became Vice President for the Biologics Consulting Group, an internationally recognized pharmaceutical regulatory consulting company, based in California.  Jim is currently CEO of Global BioSolutions, an Australian company which provides regulatory and product development advice and assistance to biotech companies. 

Lina Jose

Quality Assurance Manager

Lina is the Quality Assurance Manager of GPN Vaccines. She has over 14 years’ experience in quality assurance, quality control, filter validation and project management across the  pharmaceutical, biotech, medical devices and manufacturing sectors. Throughout her career, Lina has developed and implemented quality management systems with a strong focus on compliance. She has extensive experience in engaging with regulators such as the FDA and TGA. As a certified auditor, she has conducted numerous internal audits for companies and external audits for vendors, and has a great deal of experience preparing sites to face audits from organisations such as FDA and ISO. Lina holds a Master’s degree in microbiology and has led and mentored microbiology teams, providing valuable technical and scientific expertise. 

Peter Mills

Director, International

Peter specialises in licensing in the life sciences sector, working closely with world-leading scientists to commercialise their technology. He has worked across all areas of the pharmaceutical, medical device, digital health and diagnostic industries and has deep international business experience in strategic licensing, clinical trial development, business development, finance and commercialisation. Most recently, Peter managed the clinical development and finances of both Syntalogic and Syntimmune (acquired by Alexion for $1.2B) in the fields of oncology and autoimmune disease.  

Josephine Wu

Director, International (Asia)

Josephine has over 17 years’ experience in global hedge fund, family office and global asset management including 10 years as an investor in listed, pre-IPO and early-stage healthcare companies across Asia. She specialises in strategic partnerships, operations, market positioning and regulatory affairs across the Pan Asia healthcare landscape. Previously, she was Head of Asia Absolute Return and Alternative Strategies at UBP, Managing Partner of Light & Salt Capital Management, Regional Portfolio Manager at Robeco Hong Kong and Yu Ming Investments, and General Partner at LR Global Partners in New York. Josephine is currently the founder and Chief Investment Officer of Aionious Management Limited, a healthcare investment company that provides business development and commercialisation strategies across Asia, specifically in China.  

Eve Martin, LLB (Hons)

Company Secretary & General Counsel

Eve is an experienced commercial and operations professional, business development manager and intellectual property lawyer. She has worked extensively in universities, in private industry and for government. Eve also has significant Company Secretarial experience as the current Company Secretary for the Digital Health CRC Ltd and having been Company Secretary for FEI Company’s two Australian subsidiaries, FEI Australia Pty Ltd and FEI Melbourne Pty Ltd and providing advice in a legal capacity to many company boards and their secretaries. Eve has extensive experience advising companies in relation to intellectual property transactions and commercialisation including on matters relating to IP ownership, licensing, assignments, collaborations, alliances, sponsorships and Corporations Act compliance. 

Protecting children and adults from the world’s foremost bacterial pathogen